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and survival after the diagnosis of aortic stenosis (AS).Background In AS, the link between BNP levels and clinical outcome is in dispute. Failure to account for the normal shifting
of BNP ranges with aging in men and women, not using hard endpoints (survival), and not enrolling large series
of patients have contributed to the uncertainty.Methods A program of prospective measurement of BNP levels with Doppler echocardiographic AS assessment during the
same episode of care was conducted. BNP ratio (measured BNP/maximal normal BNP value speciﬁc to age and
sex) >1 deﬁned BNP clinical activation.Results In 1,953 consecutive patients with at least moderate AS (aortic valve area 1.03  0.26 cm2; mean gradient
36  19 mm Hg), median BNP level was 252 pg/ml (interquartile range: 98 to 592 pg/ml); BNP ratio 2.46
(interquartile range 1.03 to 5.66); ejection fraction (EF) 57%  15%, and symptoms present in 60% of patients.
After adjustment for all survival determinants, BNP clinical activation (BNP ratio >1) independently predicted
mortality after diagnosis (p < 0.0001; hazard ratio [HR]: 1.91; 95% CI: 1.55 to 2.35) and provided incremental
power to the survival predictive model (p < 0.0001). Eight-year survival was 62  3% with normal BNP levels, 44 
3% with BNP ratio of 1 to 2 (adjusted HR: 1.49; 95% CI: 1.17 to 1.90), 25  4% with BNP ratio of 2 to 3 (adjusted
HR: 2.12; 95% CI: 1.63 to 2.75), and 15  2% with BNP ratio of 3 (adjusted HR: 2.43; 95% CI: 1.94 to 3.05). This
strong link to survival was conﬁrmed in asymptomatic patients with normal EF (adjusted HR: 2.35 [95% CI: 1.57 to
3.56] for BNP clinical activation and 2.10 [95% CI: 1.32 to 3.36] for BNP ratio of 1 to 2, 2.25 [95% CI: 1.31 to 3.87]
for BNP ratio of 2 to 3, 3.93 [95% CI: 2.40 to 6.43] for BNP ratio of 3). Aortic valve replacement was associated
with survival improved by a similarly high margin (p ¼ 0.54) with BNP ratio of <2 (HR: 0.68; 95% CI: 0.52 to 0.89;
p ¼ 0.003) or BNP ratio of >2 (HR: 0.56; 95% CI: 0.47 to 0.66; p < 0.0001).Conclusions In this large series of patients with AS, BNP clinical activation was associated with excess long-term mortality
incrementally and independently of all baseline characteristics. Higher mortality with higher BNP clinical activation,
even in asymptomatic patients, emphasizes the importance of appropriate clinical interpretation of BNP levels in
managing patients with AS. (J Am Coll Cardiol 2014;63:2016–25) ª 2014 by the American College of Cardiology
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2017overemphasized (11). Survival association with BNP levels
was analyzed in very small sets of mostly symptomatic pa-
tients (9,12,13) and thus remains undeﬁned. Another source
of uncertainty is that these pilot studies used different assays
and forms of BNP that are not well harmonized (6–9).
Considerably different absolute thresholds proposed in these
studies to stratify risk may reﬂect low power in small, variably
selected patient populations with short follow-up or may
reﬂect the instability of soft outcome endpoints (aortic valve
replacement, symptom onset, or combined endpoint
of variable cardiac events). Furthermore, normal values of
BNP for age and sex were not taken into account to afﬁrm
BNP clinical activation in excess of the normal range. Thus,
the use of BNP as a marker of AS outcome has not been
adequately validated for use in clinical practice and is not
recommended in guidelines (14,15).
Obtaining objective markers of outcome is crucial in AS.
Indeed, AS is frequent (16) and is the most common valvular
disease referred for valve replacement (17), which is the only
effective AS treatment (14,15), including transcutaneous
insertion (15). The role of symptom onset has been empha-
sized (18,19), but epidemiological changes, with the current
predominance of degenerative AS, are characterized by
elderly patients being predominantly affected and in whom
evaluation and interpretation of symptoms is challenging
(20). Therefore, objective markers of risk are crucial in that
environment; as such, BNP could play an essential role in risk
stratiﬁcation. For that purpose, it is essential to account for
the shifting normal BNP range with aging and speciﬁc to
each sex and to assess a hard endpoint, particularly mortality,
requiring a large cohort of patients diagnosed with AS.
Thus, the objectives of our study were to assess the link
between BNP values measured at diagnosis, particularly
BNP clinical activation (accounting for the normal BNP
range speciﬁc to each patient) and mortality following
the diagnosis of moderate or severe AS, and to examine
the hypothesis that BNP clinical activation independently
predicts excess mortality after adjustment for all baseline
characteristics, even in asymptomatic patients. A secondary
hypothesis examined was that higher levels of activation are
associated with more severe outcomes.
Methods
Following a pilot study of natriuretic peptides in valvular
heart diseases (21,22), we initiated a program of prospective
and systematic measurement of BNP levels with compre-
hensive Doppler echocardiographic evaluation of valve dis-
eases performed during the same episode of care. For the
purpose of the present study, we gathered 1,953 consecutive
patients who were diagnosed with moderate or severe AS
based on aortic valve area (AVA) of 1.5 cm2 by Doppler
echocardiography and who underwent this combined clin-
ical, hormonal, and Doppler echocardiographic assessment.
Patients with known rheumatic valve disease (clinically and/
or echocardiographically); congenital heart disease (exceptovert or unknown bicuspid valve
or patent foramen ovale); previ-
ous valvular surgery; acute myo-
cardial infarction within 8 weeks
preceding AS diagnosis; atrial
ﬁbrillation with rapid ventricular
response; history or current en-
docarditis; pericarditis with or
without tamponade; sepsis; se-
vere liver, kidney, or brain disease
except old stroke; hyperparathy-
roidism; or Cushing disease were
excluded. Non-U.S. citizens were excluded to ensure ho-
mogeneous Social Security death data. The study was
approved by our institutional review board.
Clinical data. Clinical data were collected by the patients’
personal physicians during the same episode of care as the
Doppler echocardiographic and hormonal assessment. The
Charlson score index was calculated as previously published
(23). Symptomatic patients presented with syncope or near
syncope, dyspnea, and/or probable or classic angina.
Doppler echocardiography. All patients underwent
comprehensive Doppler echocardiography using standard
ultrasound systems, including interrogation from all possible
windows (24). All measurements and calculations were per-
formed as recommended by echocardiographic societies’
recommendations (25). After measurement in systole of
aortic annulus diameter, ﬂow velocity and time velocity in-
tegral of left ventricular outﬂow tract by pulsed-wave
Doppler, and AS jet by continuous-wave Doppler, we
measured peak jet velocity and mean gradient and calculated
AVA by continuity equation as an absolute value and indexed
to body surface area. AS severity was graded according to
current guidelines (14) and recent community studies (20)
as moderate AS with AVA of 1.0 to 1.5 cm2 or severe AS
with AVA of 1.0 cm2.
Laboratory data. Venous blood samples were drawn from
an antecubital vein into chilled ethylenediaminetetraacetic
acid Vacutainer test tubes (Becton, Dickinson and Com-
pany, Franklin Lakes, New Jersey). Plasma separation was
immediately performed at 4C, and plasma samples were
frozen at 70C until assay. Plasma BNP levels were
determined by immunoenzymatic assay (Triage, Biosite Inc.,
San Diego, California) within 3 days. The ratio between
measured serum BNP level and maximal normal BNP level
for age and sex (BNP ratio) was calculated for each patient
(26). The maximal normal values of BNP speciﬁc to age and
sex were derived from Mayo Clinic laboratory procedures.
Patients with elevated BNP levels (i.e., BNP ratio >1) were
considered as displaying BNP clinical activation.
Endpoints. The primary endpoint of this study was the
overall mortality after diagnosis, and the secondary endpoint
was mortality under medical treatment. This secondary
endpoint was assessed in the whole cohort with censoring at
the time of aortic valve replacement (AVR) if performed.
Due to the large size of our series, we elected to follow up
Table 1 Baselines Characteristics of the Population
Whole Cohort
(n ¼ 1,953)
Asymptomatic
Isolated AS Group*
(n ¼ 565)
Clinical data
Age, yrs 76  12 74  13
Male 1,081 (55) 310 (55)
Body mass index, kg/m2 28.9  6.4 28.0  5.8
Body surface area, m2 1.91  0.25 1.89  0.23
Diastolic blood pressure, mm Hg 68.6  11.8 68.8  10.4
Systolic blood pressure, mm Hg 127.0  20.6 128.6  19.3
Heart rate, beat/min 71  14 68  13
Atrial ﬁbrillation 365 (20) 62 (11)
Diabetes 595 (30) 141 (25)
Hypertension 1,355 (70) 357 (63)
Old myocardial infarction 398 (20) 0
Chronic pulmonary disease 629 (32) 130 (23)
Chronic kidney disease 699 (36) 137 (24)
Previous open-heart surgery 132 (7) 23 (4)
Charlson comorbidity index 4.2  3.6 3.1  3.2
Symptoms 1165 (60) 0
Blood sample data
BNP, pg/ml 252 (98–592) 138 (58–324)
BNP ratio 2.46 (1.03–5.66) 1.42 (0.63–3.1)
Activated BNP 1472 (75) 347 (61)
Creatinine, mg/dl 1.2 (1.0–1.4) 1.1 (0.9–1.3)
Hemoglobin, g/dl 12.8 (11.4–14.1) 13.4 (12.0–14.5)
Echocardiographic data
LV end-diastolic diameter, mm 49.9  7.2 47.7  5.4
LV end-systolic diameter, mm 33.2  9.1 29.3  4.9
Peak aortic jet velocity, m/s 3.78  0.95 3.94  0.95
Mean gradient, mm Hg 36  19 39  19
AVA, cm2 1.03  0.26 1.04  0.26
AVAi, cm2/m2 0.55  0.15 0.55  0.14
LV ejection fraction, % 57  15 65  7
LV ejection fraction <50% 414 (22) 0
Values are mean  SD, n (%), or median (interquartile range). *Asymptomatic isolated AS group
was deﬁned as asymptomatic AS with normal ejection fraction and no previous myocardial
infarction.
AS ¼ aortic stenosis; AVA ¼ aortic valve area; AVAi ¼ indexed aortic valve area; BNP ¼ B-type
natriuretic peptide; LV ¼ left ventricular.
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2018on patients using electronic records of events from internal
computerized databases and from the Social Security Death
Index. For maximizing interrogation of the central Social
Security Death Index database, a multiple demographic
list (such as ﬁrst and last name, date of birth, and Social
Security number) and a delay of 1 year between interrogation
and closing follow-up date were used (27,28).
Statistical analysis. Results are expressed as mean  SD,
median with interquartile range, or percentage when appro-
priate. Continuous variables were tested for distribution
normality with the Shapiro-Wilk test. Because BNP absolute
values and BNP ratio were not normally distributed, natural
log transformations of BNP and BNP ratio were used for
BNP continuous variable analyses (unless otherwise speciﬁed).
BNP ratio was also categorically analyzed. Analysis of survival
used patients with normal BNP levels as reference compared
with those with BNP clinical activation overall or stratiﬁed
into 3 groups (1 to 2, 2 to 3, or 3), or quintiles of elevated
BNP ratio distribution.
Univariable and multivariable models used Cox propor-
tional hazards for survival analysis. To analyze BNP incre-
mental value, we deﬁned a background model to predict
mortality including age, sex, body surface area, atrial ﬁbril-
lation, Charlson score index, symptoms, creatinine level,
hemoglobin level, systolic blood pressure, indexed AVA, and
left ventricular ejection fraction (LVEF). All variables in the
Cox models veriﬁed the proportional hazards assumption on
the basis of inspection of trends in the Schoenfeld residuals
(all p > 0.15). AVR was used as a time-dependent covariate
in the multivariable Cox proportional hazards models. The
time between diagnosis and AVR was considered as medical
treatment follow-up. Using age, sex, creatinine level, he-
moglobin level, LVEF, mean gradient, indexed AVA, atrial
ﬁbrillation, systolic blood pressure, body surface area, coro-
nary artery disease, previous myocardial infarction, hyper-
tension, previous open heart surgery, diabetes, renal disease,
and symptoms, we calculated case-weight estimation with a
logistic regression model to predict the inverse probability of
having an AVR. With this inverse probability of treatment
weighting, baseline characteristics were compared between
patients with and without AVR during follow-up with the
use of weighted Student t test or weighted Wilcoxon rank-
sum test for continuous variables and weighted chi-square
test or Fisher exact test for categorical variables, as appro-
priate. Inverse probability-weighted Cox multivariable
models were used to analyze potential impact of AVR overall
and stratiﬁed by BNP ratio <2 or 2.
BNP additional impact on survival after diagnosis was
analyzed by adding BNP (expressed as a continuous or
categorical variable) to the background survival model and
assessing model incremental power using the likelihood ratio
test. Survival models are presented with BNP hazard ratio
(HR) and 95% CI.
A p value <0.05 was considered statistically signiﬁcant.
Statistical analyses were performed with JMP 9.1 and SPSS
20.0 software.Results
Baseline characteristics. The baseline characteristics of
the entire cohort are presented in Table 1, left column.
Consistent with typical characteristics of patients diag-
nosed with moderate to severe AS, age was 76  12 years
and 1081 (55%) patients were male. With LVEF of 57 
15%, the AS characteristics were coherent with AVA was
1.03  0.26 cm2, mean gradient 36  19 mm Hg and
peak velocity 3.78  0.95 m/s. In term of comorbidity,
prevalence of hypertension (70%), atrial ﬁbrillation (20%),
diabetes (30%), chronic pulmonary disease (32%), and
chronic kidney disease (36%) were as expected in a popu-
lation of that age. Median (interquartile range) of BNP
was 252 (98 to 592) pg/ml and that of BNP ratio was
2.46 (1.03 to 5.66), with BNP clinical activation noted
in 75.4% of patients (20.0% having BNP ratio of 1 to 2,
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201911.6% 2 to 3, and 43.8% >3). The distribution in quintiles
of patients with BNP ratio >1 corresponds to thresholds
of BNP ratio of 1.71, 2.87, 4.78, and 9.28. Among the
1,953 patients, 565 (29%) were asymptomatic with pre-
served LVEF (i.e., >50%) and no history of myocardial
infarction (Table 1).
Clinical activation of BNP and overall survival in the
whole cohort. During a mean follow-up of 3.8  2.4
years, there were 828 AVRs (1,125 patients had only
follow-up under medical management) and 1,070 deaths.
Overall survival at 2, 5, and 8 years was 73%  1%, 49% 
1%, and 34%  2%. In univariable analysis, expressed as
continuous variables, ln BNP and ln BNP ratio were
associated with increased overall mortality (HR: 1.68 [95%
CI: 1.60 to 1.77; p < 0.0001] and HR: 1.54 [95% CI: 1.47
to 1.62; p < 0.0001], respectively). After adjustment for the
background model, ln BNP (HR: 1.40; 95% CI: 1.31 to
1.50; p < 0.0001) or ln BNP ratio (HR: 1.40; 95% CI: 1.31
to 1.50; p < 0.0001) was an independent predictor of
mortality after diagnosis. BNP clinical activation as a cat-
egorical variable was independently associated with excess
mortality (HR: 1.91; 95% CI: 1.55 to 2.35; p < 0.0001).
The addition of BNP clinical activation (or the BNP ratio
as continuous variable) to the background comprehensive
model of survival determinants, showed that BNP consid-
erably increased model predictive power (p < 0.0001).
Moreover, with a higher degree of BNP clinical activation,
excess mortality increased markedly. Indeed, analyzed as
quintiles of activated BNP, each quintile of abnormal BNP
ratio was associated with excess mortality versus normal
BNP reference group (Fig. 1A) but also showed 40% to
60% additional risk of mortality compared with each pre-
vious quintile of abnormal BNP ratio (all p  0.004)
(Fig. 2A). Furthermore, upon examination of speciﬁc
thresholds of BNP clinical activation (Table 2), all activated
subgroups incurred excess mortality, but the risk increased
from BNP ratio 1 to 2 to 2 to 3 to >3 (Figs. 1B and 2B).
The adjusted HRs of 1.49 to 2.12 to 2.43 signiﬁed that,
compared with patients with BNP ratio within the normal
range, those with elevated BNP ratio lower than twice
normal had a 49% increased mortality risk independent of
other baseline characteristics, those with elevated BNP ratio
2 to 3 times normal had 112% increased mortality risk,
and those with BNP ratio higher than 3 times normal had
143% increased mortality risk (Table 2 and Fig. 1B). Sur-
vival 8 years after diagnosis was 62  3% in patients with
BNP ratio within normal range versus 24  2% for those
with BNP clinical activation (p < 0.0001), and survival
decreased proportionately with higher thresholds of BNP
activation (Fig. 3A). In estimating the therapeutic effect of
AVR, the inverse probability weight was effective at abol-
ishing the differences in baseline characteristics between
patients who underwent an AVR during follow-up and
those who did not. Within that process, after adjusting for
baseline characteristics, we found that the HR estimate of
AVR beneﬁt (time dependent) was similar in patients withBNP ratio 2 and those with BNP ratio <2 (HR: 0.56
[95% CI: 0.47 to 0.66] vs. HR: 0.68 [95% CI: 0.52 to
0.88]; p ¼ 0.54) (Fig. 4), demonstrating that the mortality
increase in those with markedly elevated BNP ratio was
similarly palliated by AVR and thus in all likelihood is
indeed related to AS.
Survival under medical management. When survival un-
der medical management was analyzed, the results were
similar. During a mean follow-up of 2.1  2.2 years under
medical management, there were 791 deaths. Overall survival
under medical management at 2, 5, and 8 years was 68 1%,
38  2%, and 21  2%. As continuous variables, adjusted
for the background model, ln BNP (HR: 1.41; 95% CI: 1.30
to 1.54; p < 0.0001) or ln BNP ratio (HR: 1.41; 1.30-1.54;
p < 0.0001) was independently predictive of mortality
(Table 2). BNP clinical activation was associated with a
similarly increased mortality under medical management
(as overall survival), with adjusted HR of 1.84 (95% CI: 1.44
to 2.35; p < 0.0001), and the addition of BNP ratio to the
model markedly increased its predictive power (p < 0.0001).
Survival under medical management 8 years after diagnosis
was 49  5% in patients without BNP clinical activation
versus 13  2% for those with BNP clinical activation
(p < 0.0001). Strata of clinical activation of BNP manifested
the same trend for higher mortality risk with medical treat-
ment when higher levels of BNP clinical activation were
present (Table 2).
Survival of isolated AS. Patients with isolated AS were
asymptomatic, had no history of myocardial infarction,
and had normal LVEF at diagnosis. For these 565 patients
with isolated AS, baseline characteristics were more
favorable than those of the entire series (Table 1), but the
results in terms of link between BNP clinical activation
and mortality were similar to those observed in the entire
series. During a mean follow-up of 4.3  2.4 years, there
were 265 AVRs and 227 deaths and overall survival at 2, 5,
and 8 years was 80  2%, 62  2%, and 54  3%. ln BNP
and ln BNP ratio were independent predictors of mortality
(both p < 0.0001) (Table 2). BNP clinical activation was
independently associated with excess mortality (adjusted
HR: 2.35; 95% CI: 1.57 to 3.56; p < 0.0001), and addition
of BNP clinical activation to the survival model markedly
increased its predictive power (p < 0.0001). The survival of
isolated AS 8 years after diagnosis was 75  4% without
versus 38  4% with BNP clinical activation (p < 0.0001).
Survival after diagnosis in the 4 deﬁned strata of BNP clin-
ical activation shown in Figure 3B demonstrates widely
divergent survival rates. Adjusted in comprehensive multi-
variable models, the degree of BNP clinical activation was
highly and progressively associated with survival, as shown
in Table 2 (right column), with mortality risk approximately
doubled versus normal BNP with BNP ratio of 1 to 2,
whereas the risk of death approximately quadrupled with
BNP ratio 3 (Table 2). When this analysis was restricted
to severe AS (mean gradient >40 mm Hg, peak aortic jet
velocity >4 m/s, or AVA <1.0 cm2), the excess mortality
Figure 1 Distribution of BNP Ratio in Each BNP Ratio Group
Normal B-type natriuretic peptide (BNP) ratio, group of elevated BNP ratio, and hazard ratio (HR) of each group of elevated BNP ratio compared with normal value of BNP ratio in
the whole cohort are shown. (A) Abnormal BNP ratio divided in quintiles; (B) BNP ratio were divided by deﬁned cut-off values. BNP ratio is presented as log scale. *Adjusted for
age, sex, body surface area, atrial ﬁbrillation, Charlson score index, symptoms, creatinine level, hemoglobin level, systolic blood pressure, indexed aortic valve area, left
ventricular ejection fraction, and aortic valve replacement as time-dependent variable.
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2020associated with degrees of BNP clinical activation was
conﬁrmed and impressive (adjusted HR: 3.02 [95% CI: 1.31
to 6.93] for BNP ratio 1 to 2, 4.64 [95% CI: 1.99 to 10.81]
for BNP ratio 2 to 3, and 7.38 [95% CI: 3.27 to 16.66] for
BNP ratio 3; all p < 0.01).Discussion
The present study analyzing the association of BNP at
diagnosis with survival after diagnosis of moderate or severe
AS has unique methodological characteristics, emphasizing
Figure 2 Overall Mortality of Each BNP Ratio Group
One-year (blue bars), 2-year (red bars), and 5-year (green bars) mortality and HR of each BNP ratio group compared with the previous one in the whole cohort are shown.
(A) Abnormal BNP ratio divided in quintiles; (B) BNP ratio were divided by deﬁned cut-off values. Numbers at the top of the bars are the numbers of deaths per group at each time
point. *Adjusted for age, sex, body surface area, atrial ﬁbrillation, Charlson score index, symptoms, creatinine level, hemoglobin level, systolic blood pressure, indexed aortic
valve area, left ventricular ejection fraction, and aortic valve replacement as time-dependent variable. Abbreviations as in Figure 1.
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2021its signiﬁcance. First, BNP measurement was integrated into
a clinical program, explaining the unique similarity between
AS characteristics in our series and in the community. BNP
expression accounting for shifting normal ranges of BNP
level with age and sex can thus be individualized to each
patient. The large power of the series allows ascertaining the
independent and incremental link between BNP and sur-
vival. Major ﬁndings of our study were the additional
prognostic value provided by BNP ratio in patients diag-
nosed with AS and the association of BNP clinical activationwith excess mortality overall, under medical management,
and in isolated AS (no symptoms or myocardial infarction
and normal EF). Another major ﬁnding is that BNP is a
quantitative marker of outcome, whereby higher degree of
BNP clinical activation predicts higher long-term mortality
in all subsets of patients with AS. The fact that AVR
is independently associated with markedly improved prog-
nosis in patients with clinically activated BNP strongly
suggests that AS and BNP values are linked and that BNP
clinical activation should be taken into account in the clinical
Table 2 Hazard Ratios, 95% CI, and p Values for Different Variables and Thresholds of BNP
Overall Mortality
Univariate Analysis
Multivariate Analysis*
Overall Mortalityy
Whole Cohort
Mortality Under
Medical Treatment
Whole Cohort
Overall Mortalityy
Asymptomatic
Isolated ASz
ln BNP HR (95% CI) 1.68 (1.60–1.77) 1.40 (1.31–1.50) 1.41 (1.30–1.54) 1.61 (1.36–1.91)
p Value <0.0001 <0.0001 <0.0001 <0.0001
ln BNP ratio HR (95% CI) 1.54 (1.47–1.62) 1.40 (1.31–1.50) 1.41 (1.30–1.54) 1.61 (1.37–1.91)
p Value <0.0001 <0.0001 <0.0001 <0.0001
Activated BNPx HR (95% CI) 3.08 (2.59–3.69) 1.91 (1.55–2.35) 1.84 (1.44–2.35) 2.35 (1.57–3.56)
p Value <0.0001 <0.0001 <0.0001 <0.0001
Activated BNP <2 times normalx HR (95% CI) 1.80 (1.44–2.25) 1.49 (1.17–1.90) 1.43 (1.08–1.90) 2.10 (1.32–3.36)
p Value <0.0001 0.001 0.008 0.002
Activated BNP 2 to
3 times normalx
HR (95% CI) 3.13 (2.48–3.96) 2.12 (1.63–2.75) 2.10 (1.55–2.86) 2.25 (1.31–3.87)
p Value <0.0001 <0.0001 <0.0001 0.003
Activated BNP 3 times normalx HR (95% CI) 4.06 (3.38–4.91) 2.43 (1.94–3.05) 2.21 (1.69–2.88) 3.93 (2.40–6.43)
p Value <0.0001 <0.0001 <0.0001 <0.0001
*Adjusted for age, sex, body surface area, atrial ﬁbrillation, Charlson score index, symptoms, creatinine level, hemoglobin level, systolic blood pressure, indexed aortic valve area, indexed stroke volume, and
LV ejection fraction. yFurther adjustment for aortic valve replacement as a time-dependent variable. zAsymptomatic isolated AS group was deﬁned as asymptomatic AS with normal ejection fraction and no
previous myocardial infarction. xCompared with normal BNP level.
Abbreviations as in Table 1.
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severe AS.
BNP in valvular heart disease. BNP is a polypeptide
secreted by the myocardium, mostly in response to stretch
(29). Measurement of BNP levels has gained wide accep-
tance as a prognostic marker in a range of conditions and has
been extensively validated in heart failure and acute coronary
syndromes (1–4). Although emulating similar approaches
with valvular diseases is tempting, pilot studies have shown
that BNP levels are much lower with valvular disease than
with heart failure (30) so that interpreting absolute BNP
levels, which is appropriate for heart failure management
(31,32), may be disputable for valve diseases. Indeed, in
valvular diseases, the low and widely discrepant thresholds
linked to outcome in pilot studies (7,21,33,34) may just be
surrogates for the known BNP-age link (26) and may fall
within the normal range for older patients. Thus, for the
BNP measure to be usable in clinical practice, it is essential
for the speciﬁc BNP assay used (35) and the patient’s
individual normal BNP range, such as by using the BNP
ratio, are recorded. This approach has the advantage of
detecting a graded response in relation to outcomes and to
afﬁrm the generally benign survival of patients with valve
diseases and BNP values within the normal range.
BNP as predictor of outcome in AS. AS is frequent (16),
and its prognosis is considerably improved by surgical or
percutaneous AVR (15,36). Symptoms have been consid-
ered main determinants of survival (18) and main triggers
for AVR (14,15) However, with aging of the population and
increasing predominance of degenerative AS (16), diagnosis
made mostly occurs in the mid-seventh decade (20) so that
symptoms (of any cause including deconditioning) or
markedly reduced activity are frequent (20). Frequent
comorbidities may also cause symptoms similar to those of
AS. Hence, clinical manifestations can be quite challengingto interpret, and objective markers of outcome are crucial
in stratifying risk at diagnosis. For this purpose, BNP level
may play an important role if its link to survival is ascer-
tained. Previous studies were small with soft endpoints and
were discordant in term of mere prognostic value (11) and
in term of usable thresholds (7–9,34) but were hypothesis
generating for the present study.
Our study, with close to 2,000 consecutive patients and
comprehensive baseline clinical and Doppler echocardio-
graphic data measured during the same episode of care,
provides ample power to analyze survival after diagnosis
and demonstrate the incremental prognostic value of BNP
level over classical outcome predictors (9). BNP clinical
activation, our main BNP characterization, with levels
higher than normal, individualized for each patient, in-
dependently predicted survival, incrementally to all other
baseline predictors, even accounting for AVR performance.
Furthermore, BNP is a quantitative determinant of sur-
vival, whereby higher BNP ratio levels, representing more
intense BNP clinical activation, indicates higher mortality
risk after diagnosis. This quantitative pattern and predic-
tive value of BNP ratio is also observed in patients without
obvious other contributors to BNP clinical activation,
speciﬁcally those with no symptoms, no overt LV
dysfunction, and no history of myocardial infarction. It
remains highly pertinent when restricted to patients with
severe AS only. Thus, it is likely that a direct link between
BNP levels and AS, rather than an extraneous cause, is key
to BNP outcome impact. This link may be debated (11),
but it is further supported by considerable survival
improvement after AVR in those with notable BNP clin-
ical activation (BNP ratio >2).
The speciﬁc subset of patients with asymptomatic AS,
normal EF, and no previous myocardial infarction is of great
interest. Initial reports suggested that outcomes were
Figure 3 Kaplan-Meier Curves of Overall Survival
The Kaplan-Meier curves of overall survival are shown according to BNP ratio strata
of patients in the whole cohort (A) and in asymptomatic patients with normal left
ventricular ejection fraction and no previous myocardial infarction (B). Percentages
represent 5-year and 8-year survival. Abbreviation as in Figure 1.
Figure 4 Cox Curves of Overall Survival
The Cox curves of overall survival are shown according to treatment (aortic valve
replacement vs. medical management) in patients with BNP ratio <2 (A) or BNP
ratio 2 (B). Inverse probability-weighted Cox models were adjusted for age, sex,
body surface area, atrial ﬁbrillation, Charlson score index, symptoms, creatinine
level, hemoglobin level, systolic blood pressure, indexed aortic valve area, left
ventricular ejection fraction, and aortic valve replacement as time-dependent
variable. Abbreviation as in Figure 1.
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2023favorable (37,38), particularly in young patients (39). How-
ever, recent reports have indicated notable sudden death
rates, even in patients truly symptom free, (40) and excess
mortality occurring over time (40,41) conﬁrmed in the
community, ruling out aberrations due to referral bias or
excess comorbidity (20). Thus, it is likely that patients with
AS, asymptomatic and with EF >50%, are heterogeneous,
some indeed with benign outcome but others with moderate
(40) or even high (41) risk that we are currently poorly
equipped to deﬁne (14,15). Although exercise testing may
contribute to decision making (42,43), it may be of limited
use in an elderly population, and BNP has a critical role to
play in this subset (6,7). Indeed, we observed that in
asymptomatic patients with AS, normal EF, and no history
of myocardial infarction, BNP activation is not onlyindependently and incrementally predictive of survival after
diagnosis but also activation magnitude is crucially important
in deﬁning prognosis. Because BNP levels have been
correlated to myocardial ﬁbrosis and its surrogate markers
(44–47), BNP clinical activation may indicate, with a simple
blood test, ongoing ventricular alterations that may ulti-
mately impact survival. Hence, we believe that detection of
BNP clinical activation represents a useful goal in clinical
practice for management of patients with AS, even asymp-
tomatic, as an incremental risk marker. No single prognostic
marker should be taken as an absolute decision maker.
Physicians should integrate all possible patient descriptors,
including age, comorbidity, frailty, AS severity and
Clavel et al. JACC Vol. 63, No. 19, 2014
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2024consequences, and patient desires into each clinical decision.
Our data clearly showed that BNP activation should be one
of the elements that participate in this comprehensive
assessment of patients with AS.
Study limitations. Our design, routine clinical practice
cohort with hormonal levels, clinical, and Doppler echo-
cardiographic data collected prospectively, but with no
mandate to arrange follow-up with investigators, maintained
the central role of the personal physician. The disadvantage
of this design is that strict plans of care by investigators
cannot be enforced; therefore, ultimate decisions are made
by patients and personal physicians. The notable advantage
of this design is the large number of patients participating,
demonstrating unique statistical power, and the limited
enrollment bias demonstrated by the similarity of the current
enrolled population with patients diagnosed with AS in the
community (20). We did not evaluate serial values of BNP;
however, now that the link of BNP to survival has been
established, future studies with serial measurements may
demonstrate additional prognostic power.
We could not secure funding to perform systematic mul-
tiple testing simultaneously, such as computed tomography,
magnetic resonance imaging, and measurement of multiple
blood markers simultaneously to calculate BNP levels.
We also did not measure NT-pro-BNP to compare predic-
tive values of these 2 assays, which may not be equivalent
prognostically in valve diseases, potentially explaining dis-
cordances in the literature (11). We believe that future
mechanistic studies should be conducted in that regard, now
that the present series has demonstrated the critical role of
BNP as a marker of survival after AS diagnosis. Comor-
bidities may inﬂuence BNP activation but were accounted
for by exclusion criteria, by adjusting for speciﬁc baseline
characteristics, and by analysis of subsets when there was
no other identiﬁed cause of BNP activation. Mild kidney or
liver disease or atrial ﬁbrillation with controlled heart rate
were included but did not affect the BNP-survival link.
Despite our large sample size and event numbers, power was
not sufﬁcient to analyze all possible subgroups in multiple
comparisons and should be addressed by future large
collaborative studies. Our study raises the question of po-
tential beneﬁt of AVR in AS with elevated BNP levels for
which a randomized control trial would be warranted.
Conclusions
In this large cohort of patients with moderate or severe AS,
BNP clinical activation, deﬁned as levels higher than the
upper limit of normal for each individual patient, was a
powerful predictor of long-term mortality, incrementally
and independently of all baseline characteristics. Moreover
BNP was a quantitative marker of outcome, whereby higher
activation predicted higher mortality, and was particularly
effective in the important subset of asymptomatic patients
with normal EF and no history of myocardial infarction.
Thus, BNP measurement and BNP ratio calculation shouldbe included for risk stratiﬁcation in clinical practice and for
consideration of AVR, which is associated with considerable
reduction of mortality, even in patients with marked BNP
clinical activation.
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